|
|
|
|
|
|
|
|
|
|
Trump’s ‘reckless’ drug pricing Executive Order threatens innovation, BIO chief
The US is doing more in the COVID-19 space than anywhere in the world due to the strength of its innovative ecosystem, says Michelle McMurry-Heath, head of trade group BIO. But such innovation is under threat due to “reckless” orders coming out of the White House.
Read Now.
|
 |
Moderna: How to make 1 billion doses of a COVID-19 vaccine
The right levels of capacity, equipment, staff, and raw materials are key in scaling up COVID-19 vaccine manufacturing says Moderna, which is moving towards making one billion doses of its mRNA candidate.
Read Now.
|
 |
Novavax teams with Serum for mass vaccine supply: ‘We can’t do that, they can’
Novavax has contracted India’s Serum Institute to make more than a billion doses of its protein-based COVID-19 vaccine candidate, pushing total capacity to 2 billion doses across its network.
Read Now.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
